Interferon regulatory factor 1–Rab27a regulated extracellular vesicles promote liver ischemia/reperfusion injury

Mu‐qing Yang, Qiang Du, Julie Goswami, Patrick R. Varley, Bin Chen, Rong‐hua Wang, Adrian E. Morelli, Donna B. Stolz, Timothy R. Billiar, Jiyu Li, David A. Geller – 23 October 2017 – The role and regulators of extracellular vesicle (EV) secretion in hepatic ischemia/reperfusion (IR) injury have not been defined. Rab27a is a guanosine triphosphatase known to control EV release. Interferon regulatory factor 1 (IRF‐1) is a transcription factor that plays an important role in liver IR and regulates certain guanosine triphosphatases.

Partial splenic artery embolization for severe hepatic myelopathy in cirrhosis

Cyriac Abby Philips, Lijesh Kumar, Philip Augustine – 23 October 2017 – Hepatic myelopathy (HM) is a devastating but rare complication of cirrhosis and portal hypertension that profoundly affects quality of life and improves only with liver transplantation. We present a case where progressive severe spastic paraparesis due to HM was substantially reversed with partial splenic artery emobilization (PSAE). (Hepatology 2018;67:1169–1171)

Benefit‐risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation

Kimberly Struble, Kirk Chan‐Tack, Karen Qi, Lisa K. Naeger, Debra Birnkrant – 23 October 2017 – On July 18, 2017, the U.S. Food and Drug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed‐dose combination (FDC), an interferon‐free, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child‐Pugh A) who have:

Telomere length and reactive oxygen species levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma

Eunkyong Ko, Hyun‐Wook Seo, Guhung Jung – 23 October 2017 – Telomeres protect chromosomal ends from deterioration and have been shown to be susceptible to shortening by reactive oxygen species (ROS)‐induced damage. ROS levels increase during the progression from early to advanced hepatocellular carcinoma (HCC). An independent study found that the telomeres in most HCC tissues lengthened during carcinogenic advancement.

Barrier to autointegration factor 1, procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 3, and splicing factor 3b subunit 4 as early‐stage cancer decision markers and drivers of hepatocellular carcinoma

Qingyu Shen, Jung Woo Eun, Kyungbun Lee, Hyung Seok Kim, Hee Doo Yang, Sang Yean Kim, Eun Kyung Lee, Taemook Kim, Keunsoo Kang, Seongchan Kim, Dal‐Hee Min, Soon‐Nam Oh, Young‐Joon Lee, Hyuk Moon, Simon Weonsang Ro, Won Sang Park, Jung Young Lee, Suk Woo Nam – 23 October 2017 – An accurate tool enabling early diagnosis of hepatocellular carcinoma (HCC) is clinically important, given that early detection of HCC markedly improves survival. We aimed to investigate the molecular markers underlying early progression of HCC that can be detected in precancerous lesions.

LiverLearning®: Thomas E. Starzl Transplant SOA: Equity in Access to Organ Allocation

As the U.S. continues to face disparities in organ allocation — due to an imbalance of supply and demand — patients who are on the waitlist for liver transplantation are increasingly at risk. This session will discuss the importance of geographic disparities in liver transplantation as well as various strategies proposed to address this critical issue in healthcare.Julie Heimbach Julie K.

LiverLearning®: General Hepatology Update

This program will provide evidence-based and practical updates for three common and/or difficult-to-manage conditions: (1) how to select patients with the lowest likelihood of recidivism for liver transplant listing, (2) how to evaluate and manage acute and chronic venous outflow disorders; and (3) how to diagnose, evaluate and involve a multidisciplinary team in the management of patients with acute liver failure.Michael R.

LiverLearning®: Cholestatic and Biliary Diseases SIG: Novel Treatment Approached to Cholestatic Liver Diseases: Theory and Practice

Recently there is an increased interest and effort in targeting novel pathways to treat cholestatic liver diseases.  Up-to-date science is needed on the new therapeutic targets and the early experiences (successes and failures) of clinical trials to foster discussion of these various approaches and identify priorities for future clinical trials.

Subscribe to